Disease staging in myeloma and the implications for therapy

Share :
Published: 24 May 2011
Views: 5751
Rating:
Save
Prof Meletios Dimopoulos, Prof Jesús San Miguel, Prof Pieter Sonneveld, Prof Heinz Ludwig
Prof Meletios Dimopoulos, Prof Jesús San Miguel, Prof Pieter Sonneveld and Pro Heinz Ludwig discuss several new issues that were highlighted during the 13th International Myeloma Workshop in Paris, including defining asymptomatic, high risk asymptomatic and ultra-high risk myeloma and the importance of observation, evaluation and risk assessment in these patient populations.

Professor Meletious Dimopoulos – University Athens, Greece
Professor Jesús San Miguel - University Hospital of Salamanca, Spain
Professor Pieter Sonneveld - Erasmus University Rotterdam, Netherlands
Professor Heinz Ludwig - Wilhelminenspital, Center for Oncology and Hematology, Vienna, Austria

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).